Payment overview · 2025
General Payments
$415.82
23 reported records · 10 companies
Healthcare provider profile · identity verified
Todd A Clayton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, MS · NPI 1386621936
Verified facts
What the public records show
CMS Open Payments records show Todd A Clayton, M.D. received $415.82 in general payments during 2025 across 23 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.21 | 19.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.22 | 17.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.22 | 12.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $50.31 | 12.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.87 | 9.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.55 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.22 | 7.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.88 | 5.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.79 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.55 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.82 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.21 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.22 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.22 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.22 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $50.31 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.87 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.55 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.22 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 756 | 204 |
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 152 |
| Losartan Potassium | Losartan Potassium | 349 | 93 |
| Omeprazole | Omeprazole | 336 | 95 |
| Metformin Hcl | Metformin Hcl | 310 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 222 | 60 |
| Gabapentin | Gabapentin | 218 | 80 |
| Lisinopril | Lisinopril | 217 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 54 |
| Meloxicam | Meloxicam | 176 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 64 |
| Carvedilol | Carvedilol | 172 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 167 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 162 | 34 |
| Potassium Chloride | Potassium Chloride | 157 | 53 |
| Sertraline Hcl | Sertraline Hcl | 152 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 41 |
| Metformin Hcl Er | Metformin Hcl | 132 | 36 |
| Ozempic | Semaglutide | 129 | 22 |
| Tramadol Hcl | Tramadol Hcl | 128 | 30 |
| Furosemide | Furosemide | 125 | 44 |
| Jardiance | Empagliflozin | 118 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 44 |
| Simvastatin | Simvastatin | 107 | 30 |
| Nifedipine Er | Nifedipine | 103 | 27 |
| Allopurinol | Allopurinol | 99 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 21 |
| Famotidine | Famotidine | 85 | 24 |
| Eliquis | Apixaban | 84 | 20 |
| Atenolol | Atenolol | 82 | 19 |
| Montelukast Sodium | Montelukast Sodium | 77 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 20 |
| Clonazepam | Clonazepam | 74 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 23 |
| Trazodone Hcl | Trazodone Hcl | 72 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 18 |
| Spironolactone | Spironolactone | 66 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 11 |
| Glimepiride | Glimepiride | 57 | 15 |
| Lovastatin | Lovastatin | 57 | 12 |
| Januvia | Sitagliptin Phosphate | 52 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 14 |
| Linzess | Linaclotide | 49 | 15 |
| Alprazolam | Alprazolam | 48 | 11 |
| Prednisone | Prednisone | 48 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 25 |
| Trulicity | Dulaglutide | 46 | 11 |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 44 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 15 |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 18 |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | 13 |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 12 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 12 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Felodipine Er | Felodipine | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Estradiol | Estradiol | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cefprozil | Cefprozil | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.82 · 23 records | Boehringer Ingelheim Pharmaceuticals, Inc. | FREESTYLE LIBRE, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Veozah, WaveWriter Alpha Prime 16, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error